Faria Ronaldo José, Cordeiro Francisca Janiclecia Rezende, Dos Santos Jéssica Barreto Ribeiro, Alvares-Teodoro Juliana, Guerra Júnior Augusto Afonso, Acurcio Francisco de Assis, da Silva Michael Ruberson Ribeiro
Pharmaceutical Services Graduate Program, Federal University of Espírito Santo, Alegre, Brazil.
Health Assessment, Technology, and Economy Group, Federal University of Espírito Santo, Alegre, Brazil.
Front Pharmacol. 2022 Apr 26;13:878972. doi: 10.3389/fphar.2022.878972. eCollection 2022.
Conventional synthetic disease-modifying antirheumatic drugs are the first-line treatment to inhibit the progression of psoriatic arthritis. Despite their widespread clinical use, few studies have been conducted to compare these drugs for psoriatic arthritis. a longitudinal study was carried out based on a centered patient national database in Brazil. Market share of drugs, medication persistence, drug costs, and cost per response were evaluated. a total of 1,999 individuals with psoriatic arthritis were included. Methotrexate was the most used drug (44.4%), followed by leflunomide (40.6%), ciclosporin (8.2%), and sulfasalazine (6.8%). Methotrexate and leflunomide had a greater market share than ciclosporin and sulfasalazine over years. Medication persistence was higher for leflunomide (58.9 and 28.2%), followed by methotrexate (51.6 and 25.4%) at six and 12 months, respectively. Leflunomide was deemed the most expensive drug, with an average annual cost of $317.25, followed by sulfasalazine ($106.47), ciclosporin ($97.64), and methotrexate ($40.23). Methotrexate was the drug being the lowest cost per response. Methotrexate had the best cost per response ratio, owing to its lower cost and a slightly lower proportion of persistent patients when compared to leflunomide. Leflunomide had a slightly higher medication persistence than methotrexate, but it was the most expensive drug.
传统合成抗风湿药物是抑制银屑病关节炎进展的一线治疗药物。尽管它们在临床中广泛使用，但针对银屑病关节炎比较这些药物的研究却很少。在巴西一个以患者为中心的全国性数据库基础上开展了一项纵向研究。评估了药物的市场份额、用药持续性、药物成本及每次反应的成本。总共纳入了1999例银屑病关节炎患者。甲氨蝶呤是使用最多的药物（44.4%），其次是来氟米特（40.6%）、环孢素（8.2%）和柳氮磺胺吡啶（6.8%）。多年来，甲氨蝶呤和来氟米特的市场份额比环孢素和柳氮磺胺吡啶更大。来氟米特的用药持续性更高（6个月和12个月时分别为58.9%和28.2%），其次是甲氨蝶呤（分别为51.6%和25.4%）。来氟米特被认为是最昂贵的药物，平均每年成本为317.25美元，其次是柳氮磺胺吡啶（106.47美元）、环孢素（97.64美元）和甲氨蝶呤（40.23美元）。甲氨蝶呤是每次反应成本最低的药物。甲氨蝶呤的每次反应成本比最佳，这是由于其成本较低，且与来氟米特相比，持续用药患者的比例略低。来氟米特的用药持续性略高于甲氨蝶呤，但它是最昂贵的药物。
